Biologics for allergic and immunologic diseases

J Allergy Clin Immunol. 2022 Oct;150(4):766-777. doi: 10.1016/j.jaci.2022.08.009. Epub 2022 Sep 2.

Abstract

Biologics or molecularly targeted drugs are often highly effective for the treatment of allergic diseases and other immunologic disorders, and they are relatively safe for short-term use as compared with conventional approaches such as the systemic use of corticosteroids. A number of studies published in 2021 consistently demonstrated their effectiveness and also revealed unanticipated findings. Among them, clinical trials for asthma and chronic obstructive pulmonary disease using biologics targeting thymic stromal lymphopoietin, IL-33, and IL-33 receptor demonstrated that these type 2 alarmin cytokines are also involved in non-type 2, noneosinophilic inflammation. Randomized controlled trials reporting the efficacies of 2 small-molecule oral drugs targeting Janus kinase-1 had a substantial impact on the management of atopic dermatitis. These drugs demonstrated superiority over dupilumab, which has previously demonstrated efficacy and is in wide use in clinical practice. As a concern, biologics are generally costly, and it should be noted that racial/ethnic minority populations may be less likely to receive biologics in the real world. Here, we have reviewed recent clinical trials and related topics dealing with the effects of biologics on allergic and immunologic diseases; in addition, we discuss how our understanding of the pathophysiology of these disorders has progressed.

Keywords: Atopic dermatitis; biologics; chronic rhinosinusitis with nasal polyps; severe asthma.

Publication types

  • Review

MeSH terms

  • Adrenal Cortex Hormones
  • Alarmins
  • Biological Products* / therapeutic use
  • Ethnicity
  • Humans
  • Hypersensitivity* / drug therapy
  • Interleukin-33
  • Janus Kinases
  • Minority Groups

Substances

  • Adrenal Cortex Hormones
  • Alarmins
  • Biological Products
  • Interleukin-33
  • Janus Kinases